SYS-MEL

SYSTEMS-BASED VIEW OF MELANOMA PROGRESSION: TOWARDS NOVEL DIAGNOSTIC (AND THERAPEUTIC) APPLICATIONS

Coordinatore	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN    more  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 17161656 Fax: +353 17161216
Nazionalità Coordinatore	Ireland [IE]
Totale costo	1˙814˙000 €
EC contributo	1˙814˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 17161656 Fax: +353 17161216	IE (DUBLIN)	coordinator	265˙186.11
2	OncoMark Limited  Organization address address: Weston Park 76 city: DUBLIN 14 postcode: - contact info Titolo: Mr. Nome: Stephen Cognome: Penney Email: send email Telefono: +353 17163666 Fax: +3531 716 3709	IE (DUBLIN 14)	participant	680˙573.73
3	PATHOLOGY DIAGNOSTICS LTD  Organization address address: COWLEY ROAD ST JOHN S INNOVATION city: CAMBRIDGE CAMBRIDGESHIRE postcode: CB4 0WS contact info Titolo: Mr. Nome: Vivian Cognome: Bolton Email: send email Telefono: +44 1223 421334 Fax: +44 1223 420 844	UK (CAMBRIDGE CAMBRIDGESHIRE)	participant	385˙051.04
4	ROYAL COLLEGE OF SURGEONS IN IRELAND  Organization address address: Saint Stephen's Green 123 city: DUBLIN postcode: 2 contact info Titolo: Dr. Nome: Markus Cognome: Rehm Email: send email Telefono: +353 14028563	IE (DUBLIN)	participant	195˙052.48
5	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Monique Cognome: Vanhaeren Email: send email Telefono: +32 16 32 95 61 Fax: +32 16 32 65 15	BE (LEUVEN)	participant	155˙980.00
6	The Beatson Institute for Cancer Research  Organization address address: "GARSCUBE ESTATE, SWITCHBACK ROAD" city: GLASGOW postcode: G61 1BD contact info Titolo: Prof. Nome: Owen Cognome: Sansom Email: send email Telefono: +141 3303696	UK (GLASGOW)	participant	132˙156.64

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Worldwide figures show that there were 160,000 incidences of melanoma in 2002, whilst 39,000 died from the disease. These upward trends are worrying, as malignant melanoma is one of the most difficult cancers to treat, due to its ability to spread quickly and its resistance to standard chemotherapeutic agents. In order to counteract this trend, targeted therapies that inhibit melanoma metastasis are required. The aim of SYS-MEL is to identify and validate prognostic and predictive biomarkers for melanoma, and to model the predictive value of these biomarkers in determining the efficacy of melanoma therapies. The central objective is to bring together four European academic institutes and two SMEs to develop 3 prognostic/predictive biomarker assays for melanoma. 3 core areas of interest are epigenetics, signalling pathways in melanoma and systems biological approaches for predicting chemotherapy responses. SYS-MEL will have three main elements: 1) Epigenomic and protein expression analysis of melanoma tissue, to validate an epigenomic signature initially identified in the FP7-funded programme Target-Melanoma; 2) In silico modelling and prediction of patient responses to decarbazine DTIC using both in vitro analysis of apoptotic pathways and a novel systems biology approach, incorporating mathematical systems modelling, quantitative biochemistry and cell biology; 3) Investigating the components of the P-Rex1 pathway that are involved in driving the migration of melanoblast cells, and thus the progression of metastasis, incorporating a computational system tailored to model complex signalling pathways. This approach will enable us to identify prognostic and predictive biomarkers for melanoma, and to develop a powerful computational modeling approach to predict disease progression and patient responses to treatment.'